Table 1 PI3K inhibitors in FL (includes completed and ongoing trials)

Single agent studies

Idelalisib

δ

[36]

II

125 [72]

4

45 [3]

11

Neutropenia [27], LFT elevation [13], diarrhea [13], PNA [7]

 + 

Copanlisib

α/δ

[39, 40]

II

142 [104]

3

59 [20]

12.5

Hyperglycemia [40], Hypertension [24], Neutropenia [24]

 + 

Duvelisib

δ/γ

[41]

II

129 [83]

3

42 [1]

9.5

Neutropenia [25], anemia [15], diarrhea [15], thrombocytopenia [12], LFT rise [5], lipase rise [7], colitis [5], PNA [5],

 + 

Umbralisib

δ, CK1ε

[44]

II

208 [117]

2

45 [5]

10.6

Neutropenia [11], diarrhea [10], LFT rise [7]

 + 

Parsaclisib

δ

NCT03126019

II

NA^c

NA^c

NA^c

NA^c

NA^c

–

Zandelisib

δ

NCT03768505

II

NA^c

NA^c

NA^c

NA^c

NA^c

–

YY-20394

δ

NCT04370405

II

NA^c

NA^c

NA^c

NA^c

NA^c

–

Tenalisib

δ/γ

NCT03711578

II

NA^c

NA^c

NA^c

NA^c

NA^c

–

Combination studies

Duvelisib + BR or R

δ/γ

[50]

I

46 [15]

2

Duvelisib + R: 62 [19], Duvelisib + BR: 58 [17]^d

Duvelisib + R: 10.7, Duvelisib + BR: 5.3^d

Neutropenia [41], rash [20], diarrhea [13]

–

Umbralisib + ublituximab

δ, CK1ε

[51]

I

75 [19]

3

44 [22]

NP

Neutropenia [28], PNA [8], diarrhea [8], abdominal pain [7], thrombocytopenia [5]

–

Copanlisib + BR or R-CHOP

α/δ

NCT03711578

III

NA^c

NA^c

NA^c

NA^c

NA^c

–

Duvelisib + nivolumab

δ/γ

NCT03892044

I

NA^c

NA^c

NA^c

NA^c

NA^c

–

Idelalisib + pembrolizumab

δ

NCT02332980

II

NA^c

NA^c

NA^c

NA^c

NA^c

–

Duvelisib + acalabrutinib

δ/γ

NCT04836832

I/II

NA^c

NA^c

NA^c

NA^c

NA^c

–

Umbralisib + pembrolizumab

δ, CK1ε

NCT03283137

I

NA^c

NA^c

NA^c

NA^c

NA^c

–

Umbralisib + ublituximab + lenalidomide

δ, CK1ε

NCT04635683

I

NA^c

NA^c

NA^c

NA^c

NA^c

–